Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Notice to Our Valued Users

Elsevier has made the difficult decision to close PracticeUpdate permanently. There will be no new content published, effective immediately. Although we are all disappointed by this news, we are incredibly grateful for your engagement and support over the years.

We thank the Editorial Boards, Advisory Boards, and Editorial Contributors for their many years of dedication to educating the healthcare community. Our appreciation extends to the many contributors who have shared their valuable time and expertise to help us parse the latest research over the years.

We encourage you to explore our other offerings such as ScienceDirect and ClinicalKey, which continue to provide valuable insights and information to help you excel in your practice.

If you have any questions or need assistance, please see the FAQs section or contact the support team. Thank you for being a part of the PracticeUpdate community!

Published in Obesity, Metabolic Syndrome, and Prediabetes and

Journal Scan / Research · May 16, 2024

Weight Loss and CVD Risk Outcomes of Semaglutide

International Journal of Obesity (2005)

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Article Citation

International Journal of Obesity (2005)

Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study

Int J Obes (Lond) 2024 May 01;48(5)662-667, W Ghusn, S Fansa, D Anazco, E Tama, B Nicolalde, K Gala, A De la Rosa, D Sacoto, L Cifuentes, A Campos, F Feres, MD Hurtado, A Acosta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

story of the week

Association Between Food Insecurity and Weight-Loss Efforts in Adults With Higher Weight

Obesity · January 06, 2025
story of the week

Early Combination Therapy With SGLT2 Inhibitors and GLP-1 Receptor Agonists or Dual GIP/GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes

Diabetes Obes Metab · December 30, 2024
story of the week

Effects of GLP-1 Receptor Agonists on Kidney and Cardiovascular Disease Outcomes

Lancet Diabetes Endocrinol · December 23, 2024
featured

Cumulative Impact of Type 2 Diabetes and Obstructive Sleep Apnoea on Cardiovascular, Liver, Diabetes-Related, and Cancer Outcomes

Diabetes Obes Metab · December 19, 2024
featured

Stepwise Cardiovascular Risk Stratification in Patients With Diabetes Using Coronary CT Assessment

J Diabetes Complicat · December 18, 2024
featured

Overweight and Obesity Are Associated With the Risk of Serious Morbidity in Adolescents

Lancet Diabetes Endocrinol · December 17, 2024
story of the week

Intensive BP Control in Patients With Type 2 Diabetes

N. Engl. J. Med · December 16, 2024
story of the week

Weight Maintenance Using Cost-Effective Antiobesity Medications After 1 Year of GLP-1 Receptor Agonist Therapy

Obesity · December 15, 2024

updated
story of the week

Effect of Dapagliflozin on Renal Haemodynamics in Patients With Type 2 Diabetes and Glomerular Hyperfiltration

Diabetes Obes Metab · December 12, 2024
story of the week

Trends in and Projections of Overweight and Obesity Prevalence Among Children, Adolescents, and Adults in the US (1990–2021 and Forecasts to 2050)

Lancet · December 02, 2024
story of the week

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction–Associated Steatotic Liver Disease

Diabetologia · November 25, 2024

Notice to Our Valued Users

Obesity, Metabolic Syndrome, and Prediabetes

Weight Loss and CVD Risk Outcomes of Semaglutide

Additional Info

Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study

Further Reading

Association Between Food Insecurity and Weight-Loss Efforts in Adults With Higher Weight

Early Combination Therapy With SGLT2 Inhibitors and GLP-1 Receptor Agonists or Dual GIP/GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes

Effects of GLP-1 Receptor Agonists on Kidney and Cardiovascular Disease Outcomes

Cumulative Impact of Type 2 Diabetes and Obstructive Sleep Apnoea on Cardiovascular, Liver, Diabetes-Related, and Cancer Outcomes

Stepwise Cardiovascular Risk Stratification in Patients With Diabetes Using Coronary CT Assessment

Overweight and Obesity Are Associated With the Risk of Serious Morbidity in Adolescents

Intensive BP Control in Patients With Type 2 Diabetes

Weight Maintenance Using Cost-Effective Antiobesity Medications After 1 Year of GLP-1 Receptor Agonist Therapy

Effect of Dapagliflozin on Renal Haemodynamics in Patients With Type 2 Diabetes and Glomerular Hyperfiltration

Trends in and Projections of Overweight and Obesity Prevalence Among Children, Adolescents, and Adults in the US (1990–2021 and Forecasts to 2050)

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction–Associated Steatotic Liver Disease

Recently Updated